COVID-19 Information Hub

Our response to COVID-19

The COVID-19 pandemic is a challenge to humanity that demands a global, united response, not just from the scientific community but also from industry, organisations, governments and every single person around the globe.

Since early 2020 when the true scale of the crisis became clear, AstraZeneca has committed to help defeat COVID-19 by harnessing and sharing our scientific knowledge and expertise to advance and accelerate the development of potential medicines to prevent or treat the virus.

We have donated nine million face masks to support healthcare workers in 49 countries, bolstered national COVID-19 testing effort and initiated clinical trials to investigate our new and existing medicines to see how they could treat the infection.

Recognising the urgent need for a vaccine to defeat the virus, we joined forces with the University of Oxford, bringing together its world-class expertise in vaccinology with our global development and manufacturing capabilities. We have accelerated clinical development and rapidly mobilised partnerships and a global supply chain that will support a broad, timely and equitable supply of a safe and effective vaccine around the world, if approved, and at no profit during the pandemic.

Complementing our vaccines approach, we also quickly mobilised research efforts to advance the development of a novel coronavirus-neutralising long-acting antibody combination (LAAB) for the potential prevention and treatment of COVID-19.

With the COVID-19 pandemic continuing to claim thousands of lives every day, we are moving quickly with our clinical trials while following strict regulatory standards, and good clinical practice and guided by robust independent data safety and monitoring boards. Given the unprecedented global impact of COVID-19 and the need for public information, we are committed to being transparent about this process.

Bolstered by our resiliency, our employees have maintained momentum, drawing motivation from our values to follow the science, do the right thing and put patients first.

Our priorities remain to ensure the continued supply of our medicines to patients, and to safeguard the health and wellbeing of all our employees and communities.